A Phase 1 dose-ranging study examining the effects of a superabsorbent polymer (CLP) on fluid, sodium and potassium excretion in healthy subjects.
BACKGROUND
CLP is an orally administered, non-absorbed, superabsorbent polymer being developed to increase fecal excretion of sodium, potassium and water in patients with heart failure and end-stage renal disease. This study was conducted to evaluate the safety of CLP, and to explore dose-related effects on fecal weight, fecal and urine sodium and potassium excretion, and serum electrolyte concentrations.


METHODS
This Phase 1, open-label, dose-escalation study included 25 healthy volunteers, who were administered CLP orally immediately prior to four daily meals for 9 days at doses of 7.5, 15.0, and 25.0 g/day (n = 5/group). An additional dose group received 15.0 g/day CLP under fasting conditions, and an untreated cohort (n = 5) served as control. Twenty-four-hour fecal and urinary output was collected daily. Samples were weighed, and sodium, potassium, and other ion content in stool and urine were measured for each treatment group. Effects on serum cation concentrations, other standard laboratory values, and adverse events were also determined.


RESULTS
At doses below 25.0 g/day, CLP was well tolerated, with a low frequency of self-limiting gastrointestinal adverse events. CLP increased fecal weight and fecal sodium and potassium content in a dose-related manner. Concomitant dose-related decreases in urinary sodium and potassium were observed. All serum ion concentrations remained within normal limits.


CONCLUSIONS
In this study, oral CLP removed water, sodium and potassium from the body via the gastrointestinal tract in a dose related fashion. CLP could become useful for patients with fluid overload and compromised kidney function in conditions such as congestive heart failure, salt sensitive hypertension, chronic kidney disease and end stage renal disease.


BACKGROUND
NCT01944007.
Lee W
LW
Henderson
Howard C
HC
Dittrich
Alan
A
Strickland
Thomas M
TM
Blok
Richard
R
Newman
Thomas
T
Oliphant
Sorbent Therapeutics Inc, 710 Lakeway Drive, Suite 290, Sunnyvale, CA 94085, USA. dalbrecht@sorbent.com.
Detlef
D
Albrecht
D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D005243:Feces / Q000737:chemistry*; D005260:Female; D064368:Healthy Volunteers; D006801:Humans; D008297:Male; D008875:Middle Aged; D011108:Polymers / Q000008:administration & dosage*; D011188:Potassium / Q000378:metabolism* / Q000652:urine; D012964:Sodium / Q000378:metabolism* / Q000652:urine; D014867:Water / Q000378:metabolism*
D011108:Polymers; D014867:Water; D012964:Sodium; D011188:Potassium